Suchit Khanijao, MD
Pulmonary Disease · Olympia, WANPI 1942635412
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,100 of the $7,336 with a category attached, or 83.1%. Intuitive Surgical accounts for 85.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $6,016 and has fallen 96.9% since, to $186 in 2025.
Across 46 payments — averaging $159.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Sanofi$291
- AstraZeneca$182
- Johnson & Johnson$167
- Regeneron Healthcare Solutions, Inc.$124
- GSK$102
- plus $181 from 5 others
What the payments were for
- Food & beverage$1,23717%
- Education$6,10083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $6,290 |
| Sanofi | 15 | $291 |
| AstraZeneca | 4 | $182 |
| Johnson & Johnson | 3 | $167 |
| Regeneron Healthcare Solutions, Inc. | 7 | $124 |
| GSK | 4 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Insmed, Inc. | 1 | $24 |
| Resmed Corp | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,336 in reported general payments places this provider in the 85th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 572 | $466,804 |
| Spiriva RespimatTiotropium Bromide | 111 | $88,325 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 101 | $60,861 |
| Fasenra PenBenralizumab | 11 | $59,034 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $38,020 |
| Spiriva HandihalerTiotropium Bromide | 28 | $25,039 |
| SymbicortBudesonide/Formoterol Fumarate | 70 | $19,444 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 111 | $18,691 |
| Incruse ElliptaUmeclidinium Bromide | 44 | $17,656 |
| Arnuity ElliptaFluticasone Furoate | 34 | $10,479 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $9,504 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 326 | $8,439 |
| Wixela InhubFluticasone Propion/Salmeterol | 43 | $8,434 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $8,123 |
| Varenicline Tartrate | 42 | $7,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $102 | $532,958723 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $20 | $157,309226 claims |
| AstraZenecaSymbicort, Bevespi Aerosphere | $182 | $25,17784 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Olympia
- Dominique PepperOlympia$212K
- Richard RedmanOlympia$86K
- Warangkhana WongbaOlympia$8K
- Jed GordenSeattle$236K
- Jiten PatelSpokane$200K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Nicholas WyshamVancouver$117K
- Colleen OverdorfBellingham$110K
- Jeffrey CarySeattle$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.